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Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses
to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for
MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during
the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic
agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early
clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of
Navelbine might be at least as effective as classical administration (once weekly, etc.). The NAME trial
compares these two strategies of Navelbine administration in MBC patients.
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Navelbine (vinorelbine; Pierre Fabre Pharmaceuticals, Castres, France) is an antineoplastic agent that has shown
efficacy in the treatment of a variety of solid tumors, including breast cancer [1–3]. Although the drug may be
given intravenously, administration by the oral route has been increasingly established for breast cancer patients
during the last decade. Results from preclinical studies suggest that the administration of small, frequent doses
of chemotherapy (metronomic chemotherapy [mCHT]) may have an effect on endothelial cells in the tumor
vasculature [4–6] in addition to the direct effects on tumor cells. Based on the available evidence, giving smaller
but more frequent doses of drugs such as vinorelbine should cause a higher dose intensity without corresponding
increases in side effects. However, whether anticancer treatment following the metronomic principle is superior to
conventional drug dosing, has not yet been validated in larger clinical trials. The NAME study, presented here, has
the potential to determine this and thus benefit patients suffering from metastatic breast cancer (MBC).
Breast cancer is among the world’s most common cancer types in women [7]. In Denmark and Norway,
approximately 4800 and 3600 new breast cancer cases are diagnosed every year, respectively. MBC is currently
incurable and cytotoxic therapy prolongs survival only modestly [8]. Very few cytotoxic regimens have shown a clear
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Figure 1. Navelbine (vinorelbine) – chemical structure.
survival benefit. The main goal for treatment of patients with MBC is to relieve symptoms and balance prolonging
survival with quality of life. The benefits and disadvantages of chemotherapy need to be carefully considered.
In light of this, MBC patients with hormone-sensitive diseases, often are treated with antihormonal regimens
(antiestrogens, aromatase inhibitors, etc.) for longer time periods. However, endocrine resistance inevitably occurs
and standard chemotherapy regimens will therefore be offered to the majority of patients.
Some of the most established types of chemotherapy for the treatment of MBC are anthracyclines and taxanes.
These drugs are unfortunately quite toxic and many patients may have used these drugs in the adjuvant setting,
somewhat limiting their efficacy in MBC. Thus, there is a great need for other effective chemotherapy regimens with
acceptable side-effect profiles that may be used in the advanced situation of the breast cancer disease. Systematic
reviews of available chemotherapeutic treatment options for MBC following progression on anthracyclines and
taxanes recommend drugs like capecitabine or vinorelbine in this setting [9]. Eribulin has recently been shown to
have some activity in this setting as well [10,11].
In HER-2 negative MBC, there is currently no single, optimal first-line chemotherapy or following line of
chemotherapy and the clinician’s choice of therapy will be made based on factors like prior therapy lines, time after
termination of adjuvant therapy, toxicity, performance status, comorbidity, age and the preferences of the individual
patient. In addition, an optimal sequence of chemotherapeutic options has not been established thus far.
The preferable side-effect profile of vinorelbine monotherapy and its proven capacity to stabilize MBC while
preserving an acceptable quality of life makes this drug a good candidate for further studies in MBC aiming
to improve outcome and side effects during treatment [12]. Its oral administration makes the drug a patient-
friendly treatment option requiring less frequent visits to the cancer ward, compared with standard intravenous
chemotherapies.
Conventional chemotherapy is often given intravenously every 3 weeks (e.g., anthracyclines, taxanes) or weekly
(taxanes). Especially the three-weekly regimens are causing considerable side effects and complications (infections,
bone marrow suppression, etc.) and may lead to hospitalization and periods without treatment to allow the patients
to recover. Long treatment intervals and also necessary treatment holidays may allow some tumor cell clones to
regrow or possibly adapt to therapy.
A novel strategy to avoid the extreme side effects of established chemotherapy regimens is the so-called ‘metro-
nomic approach’. Metronomic dosing entails frequent but small doses of chemotherapy without major treatment-
free intervals. mCHT is increasingly believed to interfere with the vascular endothelial cells in the tumors and
thereby influence tumor angiogenesis and to have stimulatory effects on the immune system [13–19]. mCHT is cur-
rently being tested in clinical trials for a variety of human cancer types, however, optimal drugs and dose schedules
have yet to be established.
Navelbine
Navelbine (vinorelbine) belongs to the group of vinca alkaloids (Figure 1), blocking cell division in the G2/M-phase
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of the cell cycle by inhibiting the assembly of microtubules, which are necessary for cell division. Vinorelbine is
considered less toxic compared with taxanes, anthracyclines and other vinca alkaloids. The drug is available for
both oral and intravenous administration.
Vinorelbine as intravenous therapy
A Phase I study reported a maximum tolerable dose of 35 mg/m2 weekly, when vinorelbine was administered as
monotherapy [20]. Granulocytopenia was the most significanr dose-limiting factor. The same report recommended
the 30 mg/m2 dose for Phase II trials. A Phase I–II study showed that the maximum tolerable dose was 40 mg/m2
when given on day 1 and 8 every 3 weeks. Thus, the dose for subsequent studies was set to 35 mg/m2 [21].
Vinorelbine is commonly used in doses of 30 mg/m2 weekly, causing clinical response rates between 40 and 60% as
first-line therapy in MBC [22–26]. A study from Denmark confirmed a clinical benefit rate of 38% with an intention-
to-treat response rate of 12% [21]. Vinorelbine given in combination with other chemotherapeutics has shown high
response rates of 62–65% and efficacy at the same level as other combinations. A prospective randomized Phase
III trial compared vinorelbine in combination with epirubicin to epirubicin alone. The combination resulted in
significantly higher response rates (50 vs 42%). The drug doses in this study were 90 mg/m2 epirubicin and
vinorelbine 25 mg/m2 on days 1 and 8 [27].
The HERNATA-trial tested vinorelbine in tandem with trastuzumab (Herceptin) in HER-2 positive breast
cancer patients and compared this combination with a combination of docetaxel and trastuzumab [28]. While the
response rates were very similar between the two arms, the combination with vinorelbine caused significantly fewer
side effects and has become the first-line therapy for HER-2 positive MBC in Denmark as a result of this study.
Vinorelbine as oral therapy
An oral formulation of vinorelbine has been developed and is now widely established in clinical practice worldwide. It
consists of a soft gelatin capsule filled with the drug. Factors affecting the bioavailability of the oral administration of
vinorelbine include solubility, absorption through the mucosa of the gastrointestinal tract, the first-pass metabolism
in mucosa and the liver and the distribution of the drug in various tissues. The bioavailability of oral vinorelbine is
43% (+/− 14%) and there is bioequivalence of 80 mg/m2 orally and 30 mg/m2 intravenously as well as 60 mg/m2
orally and 25 mg/m2 intravenously [29]. Comparative studies of intravenous administration and oral treatment
with vinorelbine have been conducted in non-small-cell lung cancer patients. In a Phase II study [30], 114 patients
with metastatic or advanced disease were randomized to either oral vinorelbine (60 mg/m2 weekly, with the option
of a dose-escalation to 80 mg/m2) or intravenous vinorelbine (30 mg/m2 weekly) monotherapy. The authors
reported a response rate of 14 and 21%, respectively and a median survival of 9.3 and 7.9 months, respectively.
The 1-year survival rate was 41 and 29%, respectively. The differences, however, were not statistically significant.
In the aforementioned study and an analysis of four other Phase II studies, toxicity was compared between oral
and intravenous administration of vinorelbine. Taken together, the evidence suggests a comparable toxicity, but
that oral administration is accompanied by a predominance of gastrointestinal side effects. Grade III–IV nausea
and vomiting occurred in 11 and 8% of the patients when treatment was given orally while the corresponding
toxicity was 0 and 3% when given intravenously. Neither trial prescribed prophylactic anti-emetics to its subjects.
The toxicity was clearly dose-related as expected. A dose increase from 60 to 80 mg/m2 was recommended only for
patients with good tolerability at the 60 mg dose. Freyer and colleagues concurred in their breast cancer study where
vinorelbine was administered orally as first-line treatment of MBC. Vinorelbine could be given as 60 mg/m2 weekly
and increased to 80 mg/m2 if there was no grade IV neutropenia. Freyer and colleagues reported a response rate of
31% [31].
The NAME trial
The Name trial is an investigator-initiated, prospective, randomized Phase II, nonblinded multinational, multicenter
study approved in Denmark and Norway. Women diagnosed with HER-2 negative, MBC (n = 200) will be enrolled
according to the study protocol.
Background & rationale for mCHT in patients with MBC
During the recent decade, we have seen an increasing interest in the concept of mCHT for MBC. Several Phase
II trials involving compounds like 5-fluororacil, capecitabine, vinorelbine, cyclophosphamide and erlotinib have
been published (Table 1) [32–37]. However, so far there are no clinical trials reported that used daily therapy with
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Table 1. Metronomic vinorelbine (Navelbine) in patients with metastatic breast cancer – selected studies.
Study Phase/clinical setting Treatment arms n Main results Ref.
Addeo et al. Phase II; first line VNB 70 mg/m2 d 1, 3 and 5 (1 week
on/1 week off)
34 ORR: 38% (28–48)
CBR: 68% (60.7–81.9)
TTP: 7.7 months (6.9–9.05)
[32]
De Iuliis et al. Pretreated with several lines; Phase II VNB 30 mg q2d; contiuously 32 ORR: 68.7%
CBR: 78.1%
TTP: 9.2 months
[37]
Addeo et al. Second line and first line with brain
mets.
TMZ 75 mg/m2 + WBRT
VNR 70 mg/m2 d 1,3 and 5 + TMZ
75 mg/m2 d 1–21
32 ORR: 52% (38–67)
CBR: 77% (62.7–88.9)
[33]
Cazzaniga et al.
(VICTOR-1 trial)
First or second line; Phase I–II VNR 40 mg d 1, 3 and 5 + CAPE
500 mg TID
34 CBR: 58.1% [34]
Cazzaniga et al.
(VICTOR-2 trial)
First or second line; Phase I–II VNR 40 mg d 1,3 and 5 + CAPE
500 mg TID
85 CBR: 81% (first line)
CBR 73% (second line)
[35]
Montagna et al.
VEX-trial
Treatment-naive patients vs
pretreated
VNR 40 mg d 1,3 and 5 + CAPE
500 mg TID + CTX 50 mg/d
42 vs
46
TTP: 26.5 vs 9.6 months [36]
CAPE: Capecitabine; CBR: Clinical benefit rate; CTX: Cyclophosphamide; d: Day; ORR: Overall response rate; qxd: Every x day; TID: Three-times daily; TMZ: Temozolomide; TTP:
Time to progression; VNR: Vinorelbine; WBRT: Whole-brain radiotherapy.
Arm A
Classical oral Navelbine:
Vinorelbine orally 60 mg/m2 days 1 and 8
(and 15), Q3 (first cycle only, increased to
80 mg/m2 days
1 and 8 Q3 if possible
Screening
Metastatic breast
cancer (MBC)
HER-2 negative
Age 18+
WHO performance
≤2
200 patients
1:1 randomization
R
an
do
m
iz
at
io
n
Centers in Denmark and Norway
Termination &
follow-up
Disease progression
Investigator decision
Withdrawal of consent
Other
Arm B
Metronomic Navelbine:
Vinorelbine orally 30 mg daily (3-week cycles)
(dose adaptation possible, if necessary)
Figure 2. Study design – the NAME trial.
Q3: Every 3 weeks.
vinorelbine for MBC. In contrast, a Phase I trial with daily therapy of vinorelbine has been published for lung
cancer patients by Gütz et al. [38]. In this dose escalation study, patients were treated daily with vinorelbine for
3 weeks followed by a 1-week break. The study included 27 patients from three German cancer centers. About
78% of the patients had stage IV disease with relapse and 93% had received prior chemotherapy. The median age
of the study population was 65 years. Patients were treated with daily doses of vinorelbine between 20 and 50 mg.
The investigators recommended a daily dose of 30 mg which could be subsequently increased to 40 mg daily for
some patients [38]. No significant accumulation of vinorelbine was observed.
Study design
The NAME trial is a randomized, open label, multicenter, multinational, Phase II clinical trial (Figure 2).
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Box 1. General inclusion and exclusion criteria (NAME trial).
Inclusion criteria
• Women with histological confirmed metastatic breast cancer. The tumor cells should be tested HER-2 negative
from the primary tumor or by biopsy of metastatic sites (measured with IHC 0-1 or IHC 2+ with consecutive,
negative FISH or CISH)
• Expected life time of more than 12 weeks
• Age 18+
• WHO performance status ≤2
• Patients, who, after oral and written information about the trial, agree to be included in the study (written
informed consent)
• Patients who are suitable for vinorelbine therapy
• Patients with only one solitary metastatic lesion must have an cytological or histological confirmation of the
diagnosis
• Negative pregnancy test (urine test)
Exclusion criteria
• Previous treatment with vinorelbine
• Parallel treatment with other anticancer therapies
• Patients with peripheral sensory neuropathy (>grade 2)
• Malabsorption syndromes or previous surgery with resection of stomach or small intestine (potentially affecting
the absorption of vinorelbine)
• Difficulty with swallowing tablets
• Pregnant or breast-feeding women
• Women with childbearing potential who are not using adequate contraception
• Clinical symptoms of CNS-metastasis requiring large doses of steroids
• Decreased bone marrow function defined by WBC count <3.0 × 109/l or neutrophil counts <1.5 × 109/l or
platelets <75 × 109/l
• Hepatic impairment defined by bilirubin >1.5-times UNL
• Renal impairment defined by serum-creatinine >1.5-times UNL
• Creatinine clearance <50 ml/min
• Other severe medical conditions, including serious heart disease, unstable diabetes mellitus, uncontrolled
hypercalcemia, clinically active infections or organ transplanations
• Participation in other clinical trials with experimental therapy arms within the last 30 days
CISH: Chromogenic in situ hybridization; FISH: Fluorescence in situ hybridization; UNL: Upper normal limit.
Primary, secondary or tertiary objectives
Treatment will be given first or second line (chemotherapy). The primary objective is to evaluate and compare the
disease control rate (complete response [CR] + partial response [PR] + stable disease [SD], SD >3 months) in the
two arms. Secondary objectives are to compare the duration of disease control, time to progression, response rate
(RR), duration of response (DR), overall survival (OS) and side effects for the two regimens. Evaluation of the global
health status/quality of life (QoL), on the basis of the EORTC QOL C30 questionnaire will be performed. At last,
a translational study to explore the potential of biomarkers during metronomic therapy is planned. The patients
will be treated until disease progression or to unacceptable high toxicity, unless the patient wishes discontinuation
of treatment for other reasons.
Key eligibility criteria
Patients with metastatic, HER-2-negative breast cancer, who experience progression of their disease and who are
candidates for first- or second-line treatment with chemotherapy are eligible for this trial. Inclusion and exclusion
criteria for the NAME trial are summarized in Box 1.
Dose & schedule of therapy
Patients enrolled in the NAME trial are randomized to one of the two following treatment arms (see also Table 2
for more details concerning the drug doses used in the two study arms):
• Control arm (arm A), or Classical treatment: Navelbine orally: vinorelbine (60 mg/m2) on day 1 and day 8
(and day 15), every 3 weeks for the first cycle followed by 80 mg/m2 on day 1 and day 8, every 3 weeks for the
following cycles.
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Table 2. Standard doses of vinorelbine according to dose levels and body surface in arm A and B of the NAME trial.
Arm A
Vinorelbine 60 mg/m2 (Day 1+8 q3) Vinorelbine 80 mg/m2 (Day 1+8 q3)
Body surface Dose level Body surface Dose level
m2 0 -1 (75% dose) -2 (50% dose) m2 0 -1 (75% dose) -2 (50% dose)
≤1.54 m2 90 mg 70 mg 40 mg ≤1.54 m2 120 mg 90 mg 60 mg
1.55–1.71 m2 100 mg 80 mg 50 mg 1.55–1.71 m2 130 mg 100 mg 60 mg
1.72–1.90 m2 110 mg 80 mg 50 mg 1.72–1.90 m2 140 mg 110 mg 70 mg
1.90 m2 120 mg 90 mg 60 mg 1.90 m2 160 mg 120 mg 80 mg
Arm B
Dose level
0 -1 -2
30 mg 20 mg 20 mg
Daily Daily Every other day
• Experimental arm (arm B), or Metronomic treatment: vinorelbine orally: with 3-week cycles of daily doses of
30 mg (patients with body surface ≤1.54 m2 or ≥65 years of age start on 20 mg vinorelbine daily).
Efficacy evaluations
The response of breast cancer patients with metastatic disease during vinorelbine therapy in the two arms of the
NAME trial will be evaluated by CT scans of the chest and abdomen according to the established RECIST criteria.
Additional MRI-scans and x-rays may be performed whenever clinical useful. At baseline, measurable and evaluable
metastases must be documented by identification of at least one bidirectionally measurable lesion. Solitary lesions
must be verified by cytology/histology. All tumor measurements will be performed approximately every 3 months
in accordance to standard procedures in oncology in both Denmark and Norway.
Safety evaluations
Adverse events (AE) and laboratory abnormalities will be monitored throughout the entire study. All AEs will be
evaluated using the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE)
V.4.0 on a scale of five grades and detailed in the electronic case report form (eCRF) forms. AEs not listed in
the CTCAE must be classified accordingly to five grades (mild, moderate, severe, life-threatening and death) as
described in the study protocol. Symptoms clearly related to the progression of the underlying malignancy will not
be reported as serious adverse events (SAEs). Hospitalization, solely due to the progression of breast cancer should
not be reported as an SAE. However, if in doubt, symptoms will be reported by the responsible oncologists as SAEs.
Due to the severity of the primary diagnosis advanced breast cancer, a number of events may be excluded from SAE
reporting like hospitalization due to bone marrow depression, fever or nausea and vomiting. These side effects will,
however, always be reported in the eCRF system. After completion of the study treatment period, the responsible
physician shall follow-up all reported AEs and SAEs according to the procedures defined in the NAME protocol.
Local laboratories will be used for all biochemical testing during the trial. All abnormalities will be reported in the
eCRF system as defined in the study protocol.
Statistical analysis
The clinical efficacy of each given therapy during the trial will be evaluated after 9 weeks on therapy (three series
of classical vinorelbine). RECIST 1.1 criteria will be used to evaluate all effects [39]. All areas of metastasis are to be
monitored and the lesions will be categorized as either measureable or nonmeasureable. The overall response rate
will also be evaluated using RECIST 1.1. Clinical chemistry alone may not be used to define response to therapy.
Descriptive statistics will be used to summarize subject characteristics, AEs and duration of responses, etc. The
response rate and its 95% CI will be reported in the planned publication.
Conclusion
Vinorelbine (Navelbine) is a well-established vinca alkaloid for the treatment of MBC. The drug is usually given
either orally or intravenously on days 1 and 8 every 3 weeks. The NAME trial aims to investigate the potential
efficacy of administering vinorelbine according to a metronomic dose schedule, meaning small doses administered
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every single day. Our hypothesis is that metronomic therapy with vinorelbine has the potential to be at least as
effective as classical vinorelbine, while with less associated side effects.
Executive summary
Background
• Breast cancer is one of the most common cancer types among women in the world. Metastatic breast cancer is
currently incurable and available chemotherapy is only prolonging survival at a modest level.
• Metronomic chemotherapy is a new approach aiming at stabilization of the advanced breast cancer disease while
decreasing side effects compared with traditional administration.
Vinorelbine/Navelbine
• Vinorelbine (Navelbine) is a well-established member of the vinca alkaloids, blocking cell division in the
G2/M-phase of the cell cycle by inhibiting the assembly of microtubules necessary for the cell division. The drug is
established both as intravenous therapy and oral therapy mostly for lung cancer and breast cancer.
The NAME trial
• The NAME trial is an investigator-initiated, multinational, prospective, randomized, open-label, Phase II trial
running in Denmark and Norway.
• A total of 200 women with HER-2 negative, metastatic breast cancer will be enrolled.
• The patients are randomized to two treatment arms:
• Arm A: first cycle: Navelbine 60 mg/m2 p.o. on days 1 and 8 (15) every 3 weeks; all following cycles: Navelbine
80 mg/m2 p.o. on days 1 and 8 every 3 weeks.
• Arm B: 30 mg Navelbine given orally and daily; (dose adaptation may be performed according to protocol).
• Treatment will be given until disease progression has been confirmed using RECIST criteria or until the
investigator terminates the treatment for other reasons according to the protocol.
• The trial has been approved by all national authorities in both Denmark and Norway.
Conclusion
• The NAME trial will clarify the role of metronomic chemotherapy with Navelbine in patients with metastatic
breast cancer.
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